Levitasbio.com

Site Inspections

Overview & More informations

LevitasBio is a biotechnology company developing novel therapeutics to improve the lives of patients with cancer and other serious diseases. The company's lead product candidate, LMB-100, is a first-in-class monoclonal antibody targeting the CD38 molecule, which is expressed on the surface of multiple myeloma cells and other hematologic malignancies. LMB-100 has demonstrated promising preclinical and clinical activity in patients with relapsed or refractory multiple myeloma, and the company is currently conducting a Phase 2 clinical trial to evaluate the safety and efficacy of LMB-100 in this patient population. In addition to LMB-100, LevitasBio is also developing other novel therapeutics targeting CD38 and other immune-regulatory molecules. The company's mission is to develop innovative therapies that improve the lives of patients with cancer and other serious diseases.

LevitasBio was founded in 2016 and is headquartered in Cambridge, Massachusetts. The company has raised over $100 million in funding from a variety of investors, including ARCH Venture Partners, Atlas Venture, and Third Rock Ventures. LevitasBio is led by a team of experienced biotechnology executives with a track record of success in developing and commercializing novel therapeutics.

According to SimilarWeb, levitasbio.com has a global rank of 498,767 and a US rank of 223,294. The website receives an estimated 13,000 monthly visits. The top traffic sources to the website are direct traffic (46.6%), search traffic (33.4%), and social media traffic (17.1%).

LevitasBio is a privately held company. The company's website does not provide any financial information. However, according to PitchBook, LevitasBio has raised $100 million in funding from a variety of investors, including ARCH Venture Partners, Atlas Venture, and Third Rock Ventures.

Domains Expiration Date Updated